drugset / Trial / NCT03047980
Trial of Sirolimus for Cognitive Impairment in Sturge-Weber Syndrome
Phase 2/3
Completed
10 enrolled
Anne Comi, MD
Children's Hospital Medical Center, Cincinnati · collabFaneca 66 Foundation · collabNational Institute of Neurological Disorders and Stroke (NINDS) · collabNational Institutes of Health (NIH) · collabPfizer · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this research study is to gain a preliminary understanding of the safety of sirolimus in Sturge-Weber syndrome (SWS) and determine best outcomes to be used to assess the utility of sirolimus for the treatment of cognitive impairments related to Sturge-Weber syndrome.
Timeline
- Start
- 2017-01
- Primary completion
- 2019-06-04
- Completion
- 2020-10-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sirolimus | Small molecule | — | Oral |